VEGFA and neoplasm: Anti-angiogenic agents, including monoclonal antibodies like bevacizumab and small molecule inhibitors like anlotinib, apatinib, and lenvatinib, inhibit the VEGF signaling pathway, exhibiting anti-tumor effects.